Oxford PharmaGenesis is a HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups. Founded in 1998, Oxford PharmaGenesis is proud to be a leading independently owned consultancy in a sector increasingly populated by corporate communications conglomerates. Now employing more than 350 dedicated HealthScience experts in offices in Oxford, London, Cardiff, Cambridge, Basel, Philadelphia and Melbourne, Oxford PharmaGenesis is a preferred supplier to 9 of the top 10 global pharmaceutical companies. Our diverse client list comprises over 50 healthcare organizations, including specialist devices, diagnostics and nutraceuticals companies, and professional societies, patient groups and academic institutions.
**Selected Publications** Professional medical writing support and the quality of randomised controlled trial reporting: a cross-sectional study. Gattrell W, Hopewell S, Young K, Farrow P, White R, Wager E, Winchester CC. *BMJ Open* 2016;6:e010329. - Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia. Gouni-Berthold I, Descamps OS, Fraass U, Hartfield E, Allcott K, Dent R, März W. *Br J Clin Pharmacol* 2016;82:1412–1443. - Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review. Pfeil AM, Allcott K, Pettengell R, von Minckwitz G, Schwenkglenks M, Szabo Z. *Support Care Cancer* 2015;23:525–45 - Journal choice: which factors do you value when submitting a manuscript? O’Regan N, Desson A, Hill C, Panayi A, Winchester CC, Baronikova S. Curr Med Res Opin 2016;32(Suppl 1):S16–17. Presented at the 12th International Meeting of the International Society of Medical Publication Professionals, National Harbor, 11–13 April 2016 - Real world evidence publications: preliminary survey of experience, attitudes and understanding in ISMPP members. White R, Male G, Koder T. Curr Med Res Opin 2016;32(Suppl 1):S12. Presented at the 12th International Meeting of the International Society of Medical Publication Professionals, National Harbor, 11–13 April 2016. - Use of Twitter and other social media to disseminate specialist clinical research: analysis using Altmetric Scott C, Young F, Farrow P. Curr Med Res 2015;31(S9):S18 [poster 24]. Presented at the 11th Annual Meeting of the International Society of Medical Publication Professionals, 27–29 April 2015.
Peer-reviewed publication planning and delivery remains the cornerstone of evidence-based medicine and is essential to all aspects of HealthScience.
While publication practices become more transparent, delivery platforms evolve and demonstrating compliance becomes more complex, one element remains constant – the need to communicate the right evidence to the right audiences at the right time.
Our consultants and writers work directly with authors and clients as part of their core teams, building relationships and understanding their perspectives. Delivering high-quality writing brings satisfaction to our authors, clients and ourselves – contributing to our low staff turnover and assuring continuity for our clients. With over 15 years of experience in publishing evidence across a wide range of therapy areas, Oxford PharmaGenesis has the power to deliver and is dedicated to your success.
Our approach to medical communications is straightforward: ensure that the right evidence reaches the right audiences at the right time.
For your product to flourish, we believe that effective HealthScience communication solutions need to be seeded at all stages of the product life cycle and to be professionally delivered through appropriate traditional or digital channels. The communication focus for your product will of course evolve with time, but whether it is advocacy development pre-launch or medical expert meetings post-launch, we can support all of your medical communications needs so that your product reaches its full potential.
Oxford PharmaGenesis Commercialization Practice applies our unique HealthScience approach to ensure that your go-to-market strategy and launch plans address all of the requirements of the external stakeholders who determine the commercial viability of your product.
We believe that the key to success is to help you to steer the commercialization process by integrating input from all directions. The value of our advice to you is that it is given unrestricted by internal pressures; this assists you in ensuring that there is a genuine need and business case for your asset early in development and in creating the appropriate frameworks within your organization to support activities throughout the product life cycle. Members of our consultancy team have personally been responsible for over 10 major product launches during their time spent in the pharmaceutical industry, and they present at leading business schools in Europe and the USA.
Oxford PharmaGenesis Ltd has not received any reviews.
Oxford PharmaGenesis Ltd has not received any endorsements.